Table 2

Baseline characteristics of the patients who developed Pneumocystis pneumoniaa
Patient Biologic Age (years) Sex RA duration (months)b Treatment duration (months)c Pulmonary disease DM DAS28 score (ESR) PSL (mg) KL-6 (U/ml)
1 IFX 71 Female 72 10 (-) (-) 6.24 2.5 ND
2 IFX 78 Female 79 1 (+) (-) 6.99 1.0 178
3 IFX 62 Male 21 20 (+) (-) 7.40 2.0 893
4 IFX 78 Female 40 1 (+) (-) 8.04 8.0 398
5 IFX 57 Male 5 2 (+) (-) 3.38 0 304
6 ETN 73 Male 2 3 (+) (-) 7.20 50 366
7 ETN 59 Female 252 15 (-) (-) 5.60 1.0 224
8 ETN 75 Male 132 5 (+) (-) 6.75 5.0 624
9 TCZ 73 Male 84 8 (+) (-) 7.00 10 445
Mean 69.5 76.3 7.2 7/9 0/9 6.51 8.83 429

aPCP developed in nine patients who did receive trimethoprim/sulfamethoxazole prophylaxis. Eight of nine patients were given glucocorticoids. -: Without DM; +: With DM; DAS28: Disease Activity Score in 28 joints; DM: Diabetes mellitus; ESR: Erythrocyte sedimentation rate; ETN: Etanercept; IFX: Infliximab; PCP: Pneumocystis pneumonia; PSL: Prednisolone; RA: Rheumatoid arthritis; TCZ: Tocilizumab. bRA duration was measured between the onset of RA and the initiation of biologics. cTreatment duration was measured between the initiation of biologics and PCP development.

Katsuyama et al.

Katsuyama et al. Arthritis Research & Therapy 2014 16:R43   doi:10.1186/ar4472

Open Data